| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
TScan Therapeutics (NASDAQ:TCRX) reported its Q4 earnings results on Wednesday, March 6, 2024 at 07:00 AM.
Here's what investors need to know about the announcement.
TScan Therapeutics beat estimated earnings by 28.000000000000004%, reporting an EPS of $-0.21 versus an estimate of $-0.29.
Revenue was up $4.12 million from the same period last year.
Last quarter the company beat on EPS by $0.21 which was followed by a 4.0% increase in the share price the next day.
Here's a look at TScan Therapeutics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.45 | -0.78 | -0.74 | -0.70 |
| EPS Actual | -0.24 | -0.51 | -0.93 | -0.78 |
| Revenue Estimate | 4.09M | 4.03M | 4.40M | 3.82M |
| Revenue Actual | 3.89M | 3.15M | 6.80M | 3.10M |
** Listen to the earnings announcement yourself by clicking here. **
To track all earnings releases for TScan Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: TCRX
